Adjuvant Testosterone Therapy in Chronic Heart Failure (ATTIC) – A Randomised Open-Label Trial

Introduction

The population share of the elderly is overgrowing worldwide. The number of the elderly is estimated to rise from 524 million in 2010 to nearly 1500 million in 2050, and most of this increase in developing countries.¹ The factors responsible for this transition are declining fertility, increased longevity and ageing of “baby boom” generations². Heart failure is a unique metabolic syndrome and is rapidly increasing in India due to the rising number of coronary artery disease (CAD), hypertension, diabetes, smoking, alcoholism and the ageing of our society¹. Due to the unavailability of any promising therapy of heart failure and despite advances in evidence-based pharmacological therapies being evaluated and tested, these patients continue to exhibit significant morbidity and excessive mortality at rates as high as 30% per year², and coupled with ongoing symptoms of fatigue, cardiac cachexia and metabolic shift towards catabolism has led to an intensive search for new therapies Due to this unmet need, novel and low-cost treatments like testosterone hormone replacement therapy are being considered for improving the lives of heart failure patients. Evidence has shown that testosterone improves lean body mass and exercise tolerance and is being investigated worldwide in improving cardiac functional capacity². Chronic heart failure is linked to maladaptive and prolonged neurohormonal and pro-inflammatory cytokine activation, resulting in a metabolic shift favouring catabolism, skeletal muscle atrophy and vasodilator incapacity. Malkin et al. discovered that testosterone replacement treatment improves functional capacity and gives symptomatic relief to men with moderately severe heart failure in a randomized, double-blind, placebo-controlled parallel study of transdermal testosterone therapy^3,4. In 2014, Mirdamadi et al. investigated the link between low testosterone levels and decreased exercise ability. They aimed to see if testosterone treatment can help individuals with stable chronic heart failure improve their clinical and cardiovascular symptoms and quality of life. In a double-blind, placebo-controlled trial, they randomized 50 male patients with congestive heart failure to receive an intramuscular (gluteal) long-acting androgen injection (1 mL of testosterone enanthate, 250 mg/ml) once every four weeks for 12 weeks or intramuscular injections of saline (1 mL of 0.9 percent w/v NaCl) with the same protocol. The researchers discovered that the two groups’ changes in body weight, hemodynamic parameters, and left ventricular dimensions echocardiographic indices were all comparable. In contrast to the placebo group, those who received testosterone had a substantial increase in 6-wall mean distance (6MWD) during the research (p-value =0.019).⁵.

This study is aimed to improve the quality of life in chronic heart failure patients in the Indian subpopulation of older men, so that transdermal supplementation of testosterone can be adopted as an adjunct therapy to the existing treatment protocols.

Material and Method

ELIGIBILITY CRITERIA

METHODOLOGY: (in accordance with SPRINT Guidelines 2013, Chan et al)²¹

Treatment arms

View this table:

• View inline
• View popup
• Download powerpoint

Participants in arm ‘A’ will be receiving 5 gm of testosterone gel on top of optimal medical therapy for 12 weeks. A nurse will dispense the drug. Testosterone is available as a 10-gram pouch. Participants will be told to squeeze half of the pouch on a finger and apply it on the deltoid region by gentle massage over an area equal to the size of one rupee coin. The drug will be withheld if the testosterone level increases to above average.

Justification of dose

The low dose of testosterone used in the study is not associated with any significant adverse effects and is postulated to improve hemodynamic characteristics in these patients. Gel preparation is preferred because of its good efficacy, lack of variability and short duration of action (which allows immediate discontinuation in case of adverse events).

Choice of comparators

Control will be similar group of patients with heart failure and will be treated based on current standard of care as established in international guidelines.

Intervention Modification

Any participant on the trial intervention, who undergoes hospitalisation or death, will be discontinued from the trial, with detailed analysis of the event in each discontinued case at the end of the study

Intervention adherence

The participant will be asked by the nurse dispensing the trial therapy to follow up with empty pouches of testosterone gel on the regular pre-defined in-person follow ups.

Endpoints

Primary endpoints

At the end of three months

• Change in Functional capacity assessment by 6-minute walk test (6MWT)

• Change in Frailty assessment by using FRIED criteria of Frailty Phenotype

• Change in Quality-of-life assessment using Kansas City Cardiomyopathy Questionnaire

Secondary endpoints

• Status of cardiac remodeling by echocardiography in improved ejection fraction as a prognostic marker for disease progression.

• Change in Status of BNP level as a surrogate marker.

• Adverse drug reactions related to testosterone transdermal patch.

Data Collection using performa after written informed consent

evaluation for all the patients will be as follows

• 1. A performed proforma will be used to collect the patients’ demographic data and examination findings, along with a detailed consent form explaining the study aims, objective, methodology, conflicts and benefits as well as harms of the particular intervention.

• 2. All patients will undergo an echocardiographic assessment at the beginning and the completion of the study.

• 3. All patients will undergo baseline laboratory investigations which will be repeated as shown in the timeline table. Testosterone will be done in a fasting state.

• 4. Functional capacity assessment; 6 min walk test (6MWT)⁶ will be performed according to standardized procedures. 6-minute walk test distance of <300 m is a simple and useful prognostic marker of subsequent cardiac death in patients with mild-to-moderate heart failure. 6 MWT is a widely available, accessible, low-cost, and well-tolerated test for the assessment of the functional capacity of patients with HF. Although the cardiopulmonary exercise test (a maximal exercise test) remains the gold standard for the evaluation of exercise capacity in patients with HF, the 6MWT (submaximal exercise test) may provide reliable information about the patient’s daily activity.

• 4. Frailty will be assessed using FRIED criteria of Frailty Phenotype (most widely used and validated frailty assessment tool)⁷. It uses five frailty criteria: weight loss, exhaustion, low physical activity, slowness, and weakness. The sum score of these five criteria classifies people into one of three frailty stages (or groups): not frail (score 0), pre-frail (score 1-2) and frail (score 3-5). Fried frailty phenotype criteria are helpful for geriatric inpatient assessment, despite diagnostic limitations, and has been validated for a large number of clinical settings

• 5. Assessment of Quality of life: This will be done and Kansas City Cardiomyopathy Questionnaire (KCCQ)⁸ comprised of the following clinically relevant domains: physical limitations, symptoms (frequency, severity and change over time, self-efficacy and knowledge, social interference, and health-related quality of life.

• 6. Insulin resistance: Glucose and insulin will be measured after overnight fasting. The blood samples will be collected in 5-ml tubes, immediately placed on ice, and transferred to the biochemistry laboratory, where samples will be processed. A commercially available kit will measure plasma insulin levels by immunoradiometric assay (Siemens ADVIA CENTAUR XP immunoassay system). Insulin resistance will be estimated by the homeostasis model assessment (HOMA-IR).⁹

• 7. Echocardiographic Evaluation: It will be done by 2-dimensional, M mode, and Doppler echocardiogram at baseline and at the end of the study by the same physician unaware of the patient’s clinical details as described previously.¹⁰

Blinding

Open-label trial

Timelines

View this table:

• View inline
• View popup
• Download powerpoint

Study Flow

• Download figure
• Open in new tab

Data management

All the data collected during the trial will be stored in an encrypted computer, whose access will be available to the authors of this study only. Due to the unavailability of a data and security management board in our institute, and as the data is going to be used only for academic purposes and there is or role of external industry conflicts of interest, the authors themselves will ensure the data quality is maintained according to best available protocols, which includes collection, storage and analysis, and maintaining a registry of all reported adverse events, including individual details of those cases which have discontinued therapy due to loss of follow up, hospitalisation or death.

Conflict of interest

The investigators have no conflicts of interest to declare. The study will have no involvement with any organization or entity with any financial interests. This study is not industry sponsored. This study will not use ay sponsored professional writers and the data will neither be accessible the industry, nor will the results be scrutinized from any external sources before publication.

Funding

Trial will be Funded by the Institutional Research Grant only, which can be contacted using AIIMS Rishikesh Research Cell, an academic institution under central Ministry of Health and Family Welfare, Government of India (contact no.-+91-0135-2462927). The Research Cell will be funding and coordinating research methodology modifications based on evidence based practices.

Discussion

This study will be an interventional study in a tertiary care centre in the northern state of India, focusing on heart failure with reduced ejection fraction, using all standard treatment protocols, and adding testosterone, which is approved and easy to use, with better compliance. The project will help in expanding the current knowledge regarding the improvements with current standard treatments and compare them to those where testosterone is added, with data on various parameters where improvement is expected, that include, but are not limited to functional capacity, metabolic parameters and objective cardiac parameters.

Despite the concern about the long-term risk of prostate cancer, currently available data do not support a link between testosterone therapy and prostate cancer. Analysis of 18 prospective studies done by Roddam et al. did not show significant changes in the level of prostate-specific antigen in any individual trial; the pooled estimates indicate a slight, albeit significant, increase in prostate-specific antigen levels.¹¹

Low testosterone levels were linked to overall and CV mortality in a meta-analysis by Araujo et al., which comprised of 12 trials with over 17,000 individuals.¹² Corona et al. included 70 papers in their meta-analysis and showed a clear association between low testosterone and high oestradiol levels and increased CVD and CV mortality risk.¹³ Muraleedharan et al. studied 581 males with Type 2 Diabetes who were followed up for six years. Testosterone treatment was given to 51 males for at least two years. Independent of comorbidities and other therapies, death rates in the low testosterone group was 20.0 percent against 9.1 percent in the normal control, and testosterone therapy decreased mortality equivalent to the controls.¹⁴ Daka et al. demonstrated that low testosterone concentrations predicted acute MI in men with T2D.¹⁵ Yeap et al. studied 3,690 older men over ten years and showed that both low and high testosterone levels were associated with all-cause mortality. Ischaemic heart disease mortality was lowered when dihydrotestosterone levels were higher.¹⁶

A review by Muraldeedharan et al. showed that testosterone level might not be pathological, but low levels may be a marker of illness.¹⁷

Certain studies pointed out that the use of testosterone can be detrimental to cardiac health, owing to its ability to proliferate myocardial tissue and retain fluids and salt, which can be detrimental in the long run. A study by Basaria et al. in 2012, known as the TOM Trial (Testosterone in Elderly Men with Mobility limitation), showed that in men with mobility limitation, the increase in serum level testosterone can be used to predict the risk of cardiovascular events, wherein those with the highest increase in free serum testosterone level showed the most significant risk of such events, however, logistic regression analysis of this study showed such effect is not significant to owe any harm. Other studies do not support this adverse profiling.¹⁸ An extensive review of the literature published between 1940 and 2014 found only four studies that reported increased CV risk.¹⁹

Owing to its proven safety profile, lower cost and wide availability, the use of testosterone has the potential to become a valuable adjuvant to the current standard of care in heart failure, as even the current regimen is not very effective, and all the approved mechanical strategies to relieve heart failure are expensive, albeit not shown to be more effective than conventional treatment modalities.²⁰ Owing to this unmet need for a newer, more effective intervention, our study aims to fill this lacuna by including improvement not just in objective parameters but also symptom-based questionnaires to, in a way, some extent proves benefit in quality of life in such elderly patient, which in recent past has become our prime aim as physicians caring for the increasing population of elderly.